Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Melan-A, a new melanocytic differentiation marker.

Busam KJ, Jungbluth AA.

Adv Anat Pathol. 1999 Jan;6(1):12-8. Review.

PMID:
10197235
2.

Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

J Clin Oncol. 2012 May 20;30(15):1835-41. doi: 10.1200/JCO.2011.40.2271. Epub 2012 Apr 23.

PMID:
22529253
3.

HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.

Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.

J Immunol. 2012 Mar 1;188(5):2102-10. doi: 10.4049/jimmunol.1101807. Epub 2012 Jan 30.

4.

Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells.

Mahmood MN, Lee MW, Linden MD, Nathanson SD, Hornyak TJ, Zarbo RJ.

Mod Pathol. 2002 Dec;15(12):1288-93.

5.
6.

Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.

Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL, Jungbluth AA.

Am J Surg Pathol. 1998 Aug;22(8):976-82.

PMID:
9706977
7.
8.

Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ.

Kim J, Taube JM, McCalmont TH, Glusac EJ.

J Cutan Pathol. 2011 Oct;38(10):775-9. doi: 10.1111/j.1600-0560.2011.01763.x. Epub 2011 Jul 29.

PMID:
21797920
9.

Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.

Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE, Xu X.

Am J Dermatopathol. 2004 Dec;26(6):452-7.

PMID:
15618925
10.
11.

TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.

Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM.

J Immunol. 2011 Sep 1;187(5):2453-63. doi: 10.4049/jimmunol.1101268. Epub 2011 Jul 27.

12.

S100, HMB-45, and Melan-A negative primary melanoma.

Shinohara MM, Deubner H, Argenyi ZB.

Dermatol Online J. 2009 Sep 15;15(9):7.

PMID:
19930994
13.

Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes.

Satzger I, Völker B, Meier A, Schenck F, Kapp A, Gutzmer R.

Am J Surg Pathol. 2007 Aug;31(8):1175-80.

PMID:
17667539
14.

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.

Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H, Walker C, Young LS, Steven NM.

Gene Ther. 2011 Jun;18(6):584-93. doi: 10.1038/gt.2011.1. Epub 2011 Feb 10.

PMID:
21307889
15.

Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.

Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ.

Am J Surg Pathol. 2002 Jan;26(1):82-7.

PMID:
11756773
16.

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.

Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller B, Schulz S, Bernhard H.

Int J Cancer. 2012 May 15;130(10):2327-36. doi: 10.1002/ijc.26272. Epub 2012 Jan 11.

17.

Melan-a-positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin.

Beltraminelli H, Shabrawi-Caelen LE, Kerl H, Cerroni L.

Am J Dermatopathol. 2009 May;31(3):305-8. doi: 10.1097/DAD.0b013e31819d3769.

PMID:
19384076
18.

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J.

Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24.

19.

Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial.

Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, Ragavendra N, Raman S, Seja E, Rosario D, Miles S, Diamond DC, Qiu Z, Obrocea M, Bot A.

Clin Cancer Res. 2011 May 1;17(9):2987-96. doi: 10.1158/1078-0432.CCR-10-3272. Epub 2011 Mar 8.

20.

Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin.

Thum C, Hollowood K, Birch J, Goodlad JR, Brenn T.

J Cutan Pathol. 2011 Dec;38(12):954-60. doi: 10.1111/j.1600-0560.2011.01798.x.

PMID:
22050092

Supplemental Content

Support Center